Aspire Private Capital’s Puma Biotechnology PBYI Stock Holding History

Aspire Private Capital’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-700	Closed	-$1.78K	–	490
2024 Q3	$1.78K	Hold	700	–	–	﹤0.01%	555
2024 Q2	$2.28K	Hold	700	–	–	﹤0.01%	544
2024 Q1	$3.71K	Hold	700	–	–	﹤0.01%	520
2023 Q4	$3.03K	Hold	700	–	–	﹤0.01%	522
2023 Q3	$1.84K	Hold	700	–	–	﹤0.01%	569
2023 Q2	$2.47K	Hold	700	–	–	﹤0.01%	526
2023 Q1	$2.16K	Hold	700	–	–	﹤0.01%	535
2022 Q4	$2.96K	Hold	700	–	–	﹤0.01%	490
2022 Q3	$2K	Hold	700	–	–	﹤0.01%	521
2022 Q2	$2K	Hold	700	–	–	﹤0.01%	503
2022 Q1	$2K	Hold	700	–	–	﹤0.01%	508
2021 Q4	$2K	Buy	700 +200	+40%	+$868	﹤0.01%	536
2021 Q3	$4K	Buy	+500	New	+$3.74K	﹤0.01%	418
2021 Q1	–	Sell	-500	Closed	-$5K	–	592
2020 Q4	$5K	Hold	500	–	–	﹤0.01%	301
2020 Q3	$5K	Buy	+500	New	+$5.09K	﹤0.01%	313
2020 Q1	–	Sell	-500	Closed	-$4K	–	417
2019 Q4	$4K	Buy	500 +300	+150%	+$2.48K	﹤0.01%	321
2019 Q3	$2K	Buy	+200	New	+$2.16K	﹤0.01%	367

Other funds holding PBYI

ACA

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Aspire Private Capital's PBYI Position: Q4 2024 in Review

Aspire Private Capital sold out of Puma Biotechnology (PBYI) in Q4 2024, closing a stake of 700 shares — an estimated $1.78K sold.

Aspire Private Capital first reported a position in PBYI in Q3 2019 and held it in 17 quarters. The position peaked at $5K in Q4 2020. 112 funds tracked by Wall St. Rank hold PBYI as of Q4 2024.

Aspire Private Capital reported no remaining Puma Biotechnology position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 700 Puma Biotechnology shares in Q4 2024, an estimated $1.78K.
Aspire Private Capital first reported a position in Puma Biotechnology in Q3 2019 and held it in 17 quarters.
Aspire Private Capital's Puma Biotechnology position peaked at $5K in Q4 2020.
112 funds tracked by Wall St. Rank held Puma Biotechnology as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.